TG Therapeutics, Inc. (TGTX) stock
TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$66.12+3.41 (+5.44%)
Close on Nov 18, 2026Market cap $10.12BP/E 24.1Yield –
TG Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
TG Therapeutics's pe ratio was 24.0× on Nov 11, 2026, against 12.0× a year earlier. Over the last 4 years it ranged from 0.2× to 303.4×, with a median of 19.8×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 24.0× | +13.3 |
| 2025 | Dec 31, 2025 | 10.7× | −30.4 |
| 2024 | Oct 31, 2024 | 41.1× | +40.4 |
| 2012 | Jan 31, 2012 | 0.7× | +0.5 |
| 2011 | Dec 30, 2011 | 0.2× | – |
See a number that looks wrong?